These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27230837)

  • 1. [The pathophysiology of secondary hyperparathyroidism].
    Tokumoto M
    Clin Calcium; 2016 Jun; 26(6):821-9. PubMed ID: 27230837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of secondary hyperparathyroidism: how and why?
    Komaba H; Kakuta T; Fukagawa M
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):37-45. PubMed ID: 28044233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.
    Rodriguez M; Nemeth E; Martin D
    Am J Physiol Renal Physiol; 2005 Feb; 288(2):F253-64. PubMed ID: 15507543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical aspect of recent progress in phosphate metabolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease].
    Goto S; Fukagawa M
    Clin Calcium; 2009 Jun; 19(6):809-14. PubMed ID: 19483275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathophysiology of secondary hyperparathyroidism.].
    Kawarazaki H
    Clin Calcium; 2017; 27(4):515-520. PubMed ID: 28336827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-129 Blocks Secondary Hyperparathyroidism-Inducing Fgf23/αKlotho Signaling in Mice with Chronic Kidney Disease.
    Xu M; Li H; Bai Y; He J; Chen R; An N; Li Y; Dong Y
    Am J Med Sci; 2021 May; 361(5):624-634. PubMed ID: 33781552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors.
    Tokumoto M; Taniguchi M; Matsuo D; Tsuruya K; Hirakata H; Iida M
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S27-34. PubMed ID: 16109139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent fibroblast growth factor 23 signalling in the parathyroid glands for secondary hyperparathyroidism in mice with chronic kidney disease.
    Kawakami K; Takeshita A; Furushima K; Miyajima M; Hatamura I; Kuro-O M; Furuta Y; Sakaguchi K
    Sci Rep; 2017 Jan; 7():40534. PubMed ID: 28094278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of calcium-sensing receptor and vitamin d receptor in the pathophysiology of secondary hyperparathyroidism.
    McCann LM; Beto J
    J Ren Nutr; 2010 May; 20(3):141-50. PubMed ID: 20303786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism].
    Tanaka H; Komaba H; Fukagawa M
    Clin Calcium; 2011 Nov; 21(11):27-34. PubMed ID: 22040818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic kidney disease: mineral and bone disorder in children.
    Wesseling-Perry K; Salusky IB
    Semin Nephrol; 2013 Mar; 33(2):169-79. PubMed ID: 23465503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of secondary hyperparathyroidism.
    Cozzolino M; Pasho S; Fallabrino G; Olivi L; Gallieni M; Brancaccio D
    Int J Artif Organs; 2009 Feb; 32(2):75-80. PubMed ID: 19363778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
    Ito H; Kinugasa E
    Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidism.
    Martins P; Schmitt F; Almeida H; Frazão JM
    Nephrol Dial Transplant; 2008 Sep; 23(9):2889-94. PubMed ID: 18398016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary and tertiary hyperparathyroidism.
    Jamal SA; Miller PD
    J Clin Densitom; 2013; 16(1):64-8. PubMed ID: 23267748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.
    Hasegawa H; Nagano N; Urakawa I; Yamazaki Y; Iijima K; Fujita T; Yamashita T; Fukumoto S; Shimada T
    Kidney Int; 2010 Nov; 78(10):975-80. PubMed ID: 20844473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.
    Mizobuchi M; Ogata H; Koiwa F
    Ther Apher Dial; 2019 Aug; 23(4):309-318. PubMed ID: 30411503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.